- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03603951
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554.
This study will assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in participants with relapsed or refractory mature lymphoid neoplasms in part I, and the the efficacy in PTCL patients will be studied in Part II.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Weiwei Wang, MD
- Phone Number: +86-021-68868570
- Email: weiwei.wang@hengrui.com
Study Contact Backup
- Name: Jun Zhu, MD
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Beijing Cancer Hospital, Peking University
-
Contact:
- Lin Shen, M.D
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 70 years old (Adult, Senior)
- Part I: Histologically or cytologically confirmed Mature lymphoid neoplasms; Part II: peripheral T cell lymphomas
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Has a life expectancy of ≥12 weeks;
- Resistant to standard therapy or no standard therapy available,have indications for treatment;
- Have measurable disease (lymphoma participants,any nodes/nodal masses>1.5 cm in longest diameter (LDi) or extralymphatic sites of disease >1.0 cm in LDi;Multiple myeloma (MM) or Waldenström macroglobulinemia (WM) participants,serum M protein ≥0.5 g/dL or Bence Jones protein≥0.2 g/24 h). (dose expansion study must satisfy)
- Has sufficient tumor tissue (slides or blocks) available for testing EZH2 mutation status and expression level. (dose expansion study must satisfy)
- Diffuse large B-cell lymphoma (DLBCL) participants have immunohistochemistry test results of cell origin (germinal center B-cell-like (GCB) or non-GCB), as well as myelocytomatosis oncogene (MYC), B cell lymphoma/leukemia 2 (BCL2) and B-cell lymphoma 6 (BCL6), or provide sufficient tumor tissue for testing. (dose expansion study must satisfy)
- With adequate bone marrow function;
- With adequate renal and liver function;
- Coagulation function index:PT ≤1.5×ULN,APTT ≤1.5×ULN;
- Women of childbearing potential (WOCBP) should be proven to be negative by human chorionic gonadotropin (hCG) test in 7 days before the first dose of SHR2554. They must be willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy from the day they sign the informed consent form (ICF) to at least 30 days after receiving the last dose of study treatment. Male subjects with WOCBP partner should receive Surgical sterilization or consent to employ a highly effective method of birth control/contraception to prevent pregnancy;
- Any prior treatment-related clinically significant toxicities have resolved to ≤ Grade 1 per CTCAE version 4.03 or prior treatment-related toxicities evaluated by physicians are not clinically significant at time of enrollment.
- Participant who has provided written consent to participate in the study and ability to comply with all aspects of the protocol.
Exclusion Criteria:
- Prior exposure to other inhibitor(s) of EZH2.
- FL 3b or (potentially) transformed FL
- Participants with a presence of central nerves invasion
- Auto-transplantation within 60 days or allo-transplantation within 90 days before the first dose of study drug; >1 grade graft-versus-host disease (GVHD) or using GVHD control medicines that are not allowed by this trial;
- Major surgery or serious trauma within 4 weeks before the first dose of study drug.;
- anti-tumor agents within 4 weeks before the first dose of study drug(such as chemotherapy, radiotherapy, immunotherapy, target therapy and other clinical research);Use of Chinese Herbal within 2 weeks before the first dose of study drug;use of Glucocorticoids to anti tumor within 7 days before the first dose of study drug(equivalent to prednisone>20 mg/d);
- Has known active infection with hepatitis B virus or hepatitis C virus(HBV DNA≥2×10^3 IU/mL,HCV RNA≥10^3 IU/mL)and liver dysfunction,need the intervention of anti-virus therapy;
- Immunocompromised (i.e. has congenital immunodeficiency), including subjects known history of infection with human immunodeficiency virus (HIV) or has known active infection with tubercle bacillus;
- Has an active infection or has a temperature > 38.5°C with unknown reasons(Investigators will decide the enrollment of participants with a fever that contributed to tumors);
- Has cardiovascular impairment,including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, or stroke within 1 year prior to the planned first dose of study drug; or ventricular cardiac arrhythmia requiring medical treatment;
- abnormal of ECG with clinical significance:such as prolongation of corrected QT interval using Fridericia's formula (QTcF)(male > 450 ms、female> 470 ms);
- History of cerebrovascular accident or transient ischemic attack within 6 months;
- Has a prior malignancy other than the malignancies under study within 2 years- EXCEPTION: A subject with a history of a completely resected skin basal cell carcinoma, skin squamous-celled carcinoma, in situ cervical cancer or other in situ carcinomas, and has been relapse-free for 5 years;
- Has serious acute/chronic disease or psychic disease,such as suicide intention or action in resent 1 year; or there are abnormal conditions that will increase the risk of using or managing study drug or affect the assessment of study results or investigator's judgment;
- Staffs of institute sites directly related to the study or their family members, subordinates. Staffs of the sponsor pharmaceuticals company that directly related to the study;
- Females who are pregnant or breastfeeding.
- Inability to take oral medication, or any uncontrolled gastrointestinal condition (e.g., active gastroenteritis, chronic diarrhea, known diverticulosis, history of gastrectomy or gastric banding) that might impair the bioavailability of study drug. gastroesophageal reflux disease treated with proton pump inhibitors is eligible(should be no drug interaction);
- Use of known median or potent CYP3A4 or CYP3A5 inducers/inhibitors or P-gp inhibitors.
- Any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SHR2554 treated group
Part I:treated with escalated doses of EZH2 inhibitor SHR2554 respectively; Part II:treated with fixed dose (RP2D) SHR2554 respectively
|
SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability])(Part I)
Time Frame: through study completion, an average of about 6 months
|
The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of SHR2554 will be assessed.
|
through study completion, an average of about 6 months
|
Recommended phase 2 dose (RP2D)(Part I)
Time Frame: 30 days since the date of first dose
|
Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) will be established according to the incidence of dose-limiting toxicities (DLTs) of escalated doses of SHR2554.
|
30 days since the date of first dose
|
Objective response rate (ORR)(Part II)
Time Frame: 60 days since the date of first dose
|
assessed by independent radiology review committee (IRC)
|
60 days since the date of first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to peak (Tmax)
Time Frame: Day 1 and Day 2 of the single dose
|
Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Time to peak (Tmax) of plasma concentration
|
Day 1 and Day 2 of the single dose
|
Maximum plasma concentration (Cmax)
Time Frame: Day 1 and Day 2 of the single dose
|
Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Maximum plasma concentration (Cmax)
|
Day 1 and Day 2 of the single dose
|
Halflife (T1/2)
Time Frame: Day 1 and Day 2 of the single dose
|
Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Halflife (T1/2)
|
Day 1 and Day 2 of the single dose
|
Clearance/ bioavailability (CL/F)
Time Frame: Day 1 and Day 2 of the single dose
|
Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Clearance/ bioavailability (CL/F)
|
Day 1 and Day 2 of the single dose
|
apparent volume of distribution/bioavailability (Vd/F)
Time Frame: Day 1 and Day 2 of the single dose
|
Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): apparent volume of distribution/bioavailability (Vd/F)
|
Day 1 and Day 2 of the single dose
|
Area under curve (AUC)
Time Frame: Day 1 and Day 2 of the single dose
|
Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Area under curve (AUC)
|
Day 1 and Day 2 of the single dose
|
Area under curve, steady state (AUCss)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Area under curve, steady state (AUCss)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Maximum plasma concentration, steady state (Cmax,ss)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Maximum plasma concentration, steady state (Cmax,ss)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Time to peak, steady state (Tmax,ss)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Time to peak, steady state (Tmax,ss)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Halflife (T1/2)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Halflife (T1/2)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Apparent volume of distribution, steady state/bioavailability (Vss/F)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Apparent volume of distribution, steady state/bioavailability (Vss/F)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Clearance/ bioavailability (CL/F)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Clearance/ bioavailability (CL/F)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Accumulation index (Rac)
Time Frame: Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Accumulation index (Rac)
|
Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)
|
Objective response rate (ORR)
Time Frame: every 8 weeks through study completion, an average of about 6 months
|
Assess the response rate of subjects to the treatment of SHR2554
|
every 8 weeks through study completion, an average of about 6 months
|
Progression-free survival (PFS)
Time Frame: every 8 weeks through study completion, an average of about 6 months
|
Assess the survival condition of the subjects after the treatment of SHR2554
|
every 8 weeks through study completion, an average of about 6 months
|
Duration of Response (DoR)
Time Frame: every 8 weeks through study completion, an average of about 6 months
|
Assess the duration of complete/partial response after the treatment of SHR2554
|
every 8 weeks through study completion, an average of about 6 months
|
Time to response(TTR)(Part II only)
Time Frame: 60 days since the date of first dose
|
Assess the time to initial response of subjects to the treatment of SHR2554
|
60 days since the date of first dose
|
OS(overall survival)(Part II only)
Time Frame: 2 years since the date of first dose
|
Assess the overall survival of subjects treated by SHR2554
|
2 years since the date of first dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of escalated doses of SHR2554 on the histone H3 lysine 27 trimethylation (H3K27me3) level(Part I-exploratory endpoints)
Time Frame: day 1 of the single dose to day 1 of continuous medication cycle 2
|
Analyze the level of H3K27me3 in the peripheral blood mononuclear cells of the subjects before and after the treatment of escalated doses of SHR2554.
|
day 1 of the single dose to day 1 of continuous medication cycle 2
|
EZH2 gene mutation(Part I-exploratory endpoints)
Time Frame: within 2 weeks after the last dose
|
Assess the known mutation of EZH2 gene in tumor cells or tissues, analyze the relationship between efficacy and EZH2 mutation
|
within 2 weeks after the last dose
|
EZH2 expression level(Part I-exploratory endpoints)
Time Frame: within 2 weeks after the last dose
|
Assess EZH2 expression level in tumor tissues, analyze the relationship between efficacy and EZH2 expression level
|
within 2 weeks after the last dose
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR2554-I-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Mature Lymphoid Neoplasms
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
Curon Biopharmaceutical (Australia) Co Pty LtdNovotech (Australia) Pty LimitedTerminatedRelapsed Lymphoid Malignancies | Refractory Lymphoid MalignanciesAustralia
-
Association for Training, Education, and Research...Active, not recruitingRefractory or Relapsed Lymphoid HaemopathyFrance
-
Astellas Pharma Global Development, Inc.CompletedRelapsed Lymphoid Malignancy | Refractory Lymphoid MalignancyUnited States, Canada
-
Merck Sharp & Dohme LLCEisai Inc.Active, not recruitingRelapsed or Refractory Solid TumorsUnited States, Argentina, Australia, Belgium, Croatia, Czechia, France, Guatemala, Hungary, Israel, Italy, Korea, Republic of, New Zealand, Peru, Russian Federation, Serbia, South Africa, Spain, Sweden, Turkey
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Solid TumorsUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisInnovative Therapies For Children with Cancer ConsortiumUnknownRelapsed or Refractory Pediatric TumorFrance, Ireland, Israel, Italy, Spain
-
The University of Texas Health Science Center at...CompletedRefractory or Relapsed Solid TumorsUnited States
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalNot yet recruitingCD19-positive Relapsed or Refractory B-cell MalignanciesChina
-
EdiGene (GuangZhou) Inc.The First Affiliated Hospital of Henan University of Science and TechnologyActive, not recruitingRelapsed or Refractory B-cell Malignancy(NHL/ALL)China
Clinical Trials on SHR2554
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPeripheral T-cell Lymphoma
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingFollicular LymphomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.TerminatedProstate Cancer | Castration-resistant Prostate CancerChina
-
Chinese PLA General HospitalRecruitingRelapsed or Refractory Hodgkin LymphomaChina
-
Chinese PLA General HospitalRecruitingLymphoma | Solid TumorChina